ArticleScientific reports2022

Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer.

Rosalba Torrisi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.